Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer · Advanced Solid Tumors Harboring the KRAS G12C Mutation
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Novartis Investigative Site, Sint-Niklaas, Oost Vlaanderen, Belgium
Novartis Investigative Site, Montreal, Quebec, Canada
Novartis Investigative Site, Guangzhou, Guangdong, China
Novartis Investigative Site, Kashiwa, Chiba, Japan
Novartis Investigative Site, Koto Ku, Tokyo, Japan
Novartis Investigative Site, Kuching, Sarawak, Malaysia
Novartis Investigative Site, Seoul, South Korea
Study leads
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals